$6.74
0.07%
Downside
Day's Volatility :6.59%
Upside
6.52%
51.78%
Downside
52 Weeks Volatility :68.9%
Upside
35.5%
Period | Anavex Life Sciences Corp. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 98.84% | 6.5% | 0.0% |
6 Months | 8.06% | 7.1% | 0.0% |
1 Year | -14.39% | 9.8% | 0.0% |
3 Years | -67.49% | 14.2% | -20.2% |
Market Capitalization | 578.9M |
Book Value | $1.61 |
Earnings Per Share (EPS) | -0.5 |
PEG Ratio | 0.0 |
Wall Street Target Price | 33.67 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -19.63% |
Return On Equity TTM | -28.98% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | -0.5 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.56 |
EPS Estimate Next Year | -0.63 |
EPS Estimate Current Quarter | -0.11 |
EPS Estimate Next Quarter | -0.12 |
What analysts predicted
Upside of 399.55%
Sell
Neutral
Buy
Anavex Life Sciences Corp. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Anavex Life Sciences Corp. | 79.06% | 8.06% | -14.39% | -67.49% | 168.24% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Anavex Life Sciences Corp. | NA | NA | 0.0 | -0.56 | -0.29 | -0.2 | NA | 1.61 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Anavex Life Sciences Corp. | Buy | $578.9M | 168.24% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Anavex Life Sciences Corp.
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 76.0%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 254.0%
State Street Corporation
BlackRock Inc
Vanguard Group Inc
Geode Capital Management, LLC
Bank of America Corp
Nwam, LLC
anavex life sciences corp. is a clinical stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases. anavex is currently in a phase 2a trial for alzheimer's disease (ad) with lead therapeutic, anavex 2-73, an orally available small molecule targeting protein misfolding and cellular stress through activating the sigma-1 receptor. part a topline data of our ongoing phase 2a trial demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile. anavex 2-73 is a potential platform drug showing encouraging preclinical data rare neurodevelopmental disease: rett syndrome, as well is in epilepsy and multiple sclerosis (ms). in 2015, the company was awarded a research by the michael j. fox foundation (mjff) to study anavex 2-73 for the treatment of parkinson’s disease. headquartered in new york, anavex is an american publicly traded corporation quoted as avxl.
Organization | Anavex Life Sciences Corp. |
Employees | 40 |
CEO | Dr. Christopher U. Missling M.B.A., M.S., Ph.D. |
Industry | Health Technology |
A Spac I Acquisition Corp
$6.74
-1.46%
Keyarch Acquisition Corp
$6.74
-1.46%
Connexa Sports Technologies Inc
$6.74
-1.46%
Us Value Etf
$6.74
-1.46%
First Wave Biopharma Inc
$6.74
-1.46%
Global X Msci Next Emerging
$6.74
-1.46%
Fat Projects Acquisition Corp
$6.74
-1.46%
Capital Link Global Fintech
$6.74
-1.46%
Applied Uv Inc
$6.74
-1.46%